2016
DOI: 10.1016/j.psychres.2016.10.061
|View full text |Cite
|
Sign up to set email alerts
|

Plasma levels of Th17-related cytokines and complement C3 correlated with aggressive behavior in patients with schizophrenia

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

3
55
3

Year Published

2018
2018
2024
2024

Publication Types

Select...
4
3
1

Relationship

0
8

Authors

Journals

citations
Cited by 66 publications
(62 citation statements)
references
References 70 publications
3
55
3
Order By: Relevance
“…In the peripheral blood of patients with schizophrenia, there are validated findings on an activation of the immune-inflammatory response system (IRS), including M1 macrophagic activation, with increased production of IL-6 and tumor necrosis factor alpha (TNF)-α, T helper (Th)-1 activation, with increased levels of interferon (IFN) and IL-2, and activation of a Th-17 response with increased levels of IL-17 [29][30][31]. Schizophrenia patients also show increased levels of immune products which have immunosuppressive effects, for example the sIL-2R and sIL-1RA, to name a few [32].…”
Section: Introductionmentioning
confidence: 99%
“…In the peripheral blood of patients with schizophrenia, there are validated findings on an activation of the immune-inflammatory response system (IRS), including M1 macrophagic activation, with increased production of IL-6 and tumor necrosis factor alpha (TNF)-α, T helper (Th)-1 activation, with increased levels of interferon (IFN) and IL-2, and activation of a Th-17 response with increased levels of IL-17 [29][30][31]. Schizophrenia patients also show increased levels of immune products which have immunosuppressive effects, for example the sIL-2R and sIL-1RA, to name a few [32].…”
Section: Introductionmentioning
confidence: 99%
“…Recently, Li et al reported immune factors (C3 and Th17-related cytokines) were related to schizophrenia and aggressive behavior ( 11 ), it suggested some immune factors would be potential biomarkers for aggressive behavior with schizophrenia. The immune repertoire sequencing is a new tool for deciphering mechanisms of autoimmunity.…”
Section: Discussionmentioning
confidence: 99%
“…Although the etiology of violent and aggressive behavior in schizophrenia is multifactorial, genetic inheritance may strongly contribute to it ( 4 , 6 , 7 ). Recent studies suggested that immuno-inflammatory processes are involved in the etiology of schizophrenia ( 8 10 ) and aggressive behavior in schizophrenia ( 11 ). For example, Toxoplasma gondii antibodies have been observed in some schizophrenic populations ( 12 , 13 ), as well as increases in maternal ( 14 16 ) and childhood infections ( 17 ).…”
Section: Introductionmentioning
confidence: 99%
“…As mentioned above, all of the complement pathways converge at the point of C3 and data related to C3 levels in blood from schizophrenia patients are also controversial. Some studies found no alteration (Spivak et al, 1993) or increased levels of C3 in patients compared to controls (Maes et al, 1997;Shcherbakova et al, 1999;Hakobyan et al, 2005;Boyajyan et al, 2010), while others found a decrease and suggest a negative correlation between the serum levels of C3 and the severity of the symptoms (Wong et al, 1996;Li et al, 2016; Figure 1). The reasons for these differences are unknown, but may include either population-specific genetics and environmental risk factors or the stage of illness (acute vs. chronic).…”
Section: Complement In Schizophreniamentioning
confidence: 99%
“…Additionally, C4b binds to the complement protein FIGURE 1 | Complement activation pathways and the activity or expression of their individual components (either protein or mRNA) in schizophrenia and autism spectrum disorder (ASD). ↑ red, increased protein activity or expression in blood from patients; ↓ red, decreased protein activity or expression in blood from patients; ↑ blue, increased RNA expression in brain tissues from patients; ↓ blue, decreased RNA expression in brain tissues from patients (Spivak et al, 1989(Spivak et al, , 1993Warren et al, 1994;Wong et al, 1996;Maes et al, 1997;Shcherbakova et al, 1999;Hakobyan et al, 2005;Mayilyan et al, 2006;Corbett et al, 2007;Boyajyan et al, 2010;Momeni et al, 2012;Nardone et al, 2014;Li et al, 2016;Sekar et al, 2016;Fagan et al, 2017;Shen et al, 2018). The Figure does not distinguish between strong and weak evidence.…”
Section: Complement System Activation: a Backgroundmentioning
confidence: 99%